1. |
Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564. DOI: 10.2337/dc11-1909.
|
2. |
Kim EJ, Lin WV, Rodriguez SM, et al. Treatment of diabetic macular edema[J/OL]. Curr Diab Rep, 2019, 19(9): 68[2019-07-29]. https://pubmed.ncbi.nlm.nih.gov/31359157/. DOI: 10.1007/s11892-019-1188-4.
|
3. |
Cohen SR, Gardner TW. Diabetic retinopathy and diabetic macular edema[J]. Dev Ophthalmol, 2016, 55: 137-146. DOI: 10.1159/000438970.
|
4. |
Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management[J]. Indian J Ophthalmol, 2018, 66(12): 1736-1750. DOI: 10.4103/ijo.IJO-1240-18.
|
5. |
Coscas G, Cunha-Vaz J, Soubrane G. Macular edema: definition and basic concepts[J]. Dev Ophthalmol, 2017, 58: 1-10. DOI: 10.1159/000455264.
|
6. |
Cetin EN, Demirtaş Ö, Özbakış NC, et al. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(10): 1801-1806. DOI: 10.1007/s00417-018-4042-5.
|
7. |
Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy[J]. Expert Opin Biol Ther, 2016, 16(3): 365-374. DOI: 10.1517/14712598.2016.1131265.
|
8. |
Chung YR, Kim YH, Ha SJ, et al. Role of inflammation in classification of diabetic macular edema by optical coherence tomography[J/OL]. J Diabetes Res, 2019, 2019: 8164250[2019-12-20]. https://pubmed.ncbi.nlm.nih.gov/31930145/. DOI: 10.1155/2019/8164250.
|
9. |
付浴东, 孟旭霞, 王萍, 等. 不同光相干断层扫描分型糖尿病黄斑水肿玻璃体腔注射雷珠单抗的疗效差异及椭圆体带完整性与视力相关性观察[J]. 中华眼底病杂志, 2017, 33(2): 129-133. DOI: 10.3760/cma.j.issn.1005-1015.2017.02.005.Fu YD, Meng XX, Wang P, et al. Efficacy of intravitreal injection of ranibizumab for different patterns of optical coherence tomography of diabetic macular edema and the relationship between integrity of ellipsoidal zone and visual acuity outcomes[J]. Chin J Ocul Fundus Dis, 2017, 33(2): 129-133. DOI: 10.3760/cma.j.issn.1005-1015.2017.02.005.
|
10. |
Vujosevic S, Torresin T, Bini S, et al. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema[J]. Acta Ophthalmol, 2017, 95(5): 464-471. DOI: 10.1111/aos.13294.
|
11. |
Stela V, Caterina T, Edoardo T, et al. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids[J]. Acta Diabetol, 2020, 57(3): 287-296. DOI: 10.1007/s00592-019-01424-4.
|
12. |
Zhang J, Liang Y, Xie J, et al. Conbercept for patients with age-related macular degeneration: a systematic review[J/OL]. BMC Ophthalmol, 2018, 18(1): 142[2018-06-15]. https://pubmed.ncbi.nlm.nih.gov/29902977/. DOI: 10.1186/s12886-018-0807-1.
|
13. |
Liu Q, Hu Y, Yu H, et al. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema[J]. Retina, 2015, 35(2): 272-279. DOI: 10.1097/IAE.0000000000000300.
|
14. |
Tang J, Kern TS. Inflammation in diabetic retinopathy[J]. Prog Retin Eye Res, 2011, 30(5): 343-358. DOI: 10.1016/j.preteyeres.2011.05.002.
|
15. |
Sharma S, Mruthyunjaya P. Corticosteroids for the reatment of diabetic macular edema[J]. Cur Ophthalmol Rep, 2014, 2(4): 158-166. DOI: 10.1007/s40135-014-0051-7.
|
16. |
Mcguire PG, Rangasamy S, Maestas J, et al. Pericyte-derived sphingosine 1-phosphate induces the expression of adhesion proteins and modulates the retinal endothelial cell barrier[J/OL]. Arterioscler Thromb Vasc Biol, 2011, 31(12): e107-115[2011-09-22]. https://pubmed.ncbi.nlm.nih.gov/21940944/. DOI: 10.1161/ATVBAHA.111.235408.
|
17. |
朱少进. Müller细胞在糖尿病黄斑水肿中的作用及机制[J]. 中华实验眼科杂志, 2021, 39(4): 360-364. DOI: 10.3760/cma.j.cn115989-20200226-00111.Zhu SJ. Role and mechanism of Müller cells in diabetic macular edema[J]. Chin J Exp Ophthalmol, 2021, 39(4): 360-364. DOI: 10.3760/cma.j.cn115989-20200226-00111.
|
18. |
Vujosevic S, Torresin T, Berton M, et al. Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities[J]. Am J Ophthalmol, 2017, 181: 149-155. DOI: 10.1016/j.ajo.2017.06.026.
|
19. |
Abcouwer SF. Müller cell-microglia cross talk drives neuroinflammation in diabetic retinopathy[J]. Diabetes, 2017, 66(2): 261-263. DOI: 10.2337/dbi16-0047.
|
20. |
Wang W, Amy CY. Diabetic retinopathy: pathophysiology and treatments[J/OL]. Int J Mol Sci, 2018, 19(6): 1816[2018-06-20]. https://pubmed.ncbi.nlm.nih.gov/29925789/. DOI: 10.3390/ijms19061816.
|
21. |
Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR. net Protocol T[J]. Curr Opin Ophthalmol, 2017, 28(6): 636-643. DOI: 10.1097/ICU.0000000000000424.
|
22. |
陈沁芸, 张学东. 评估糖尿病黄斑水肿抗血管内皮生长因子药物治疗预后的临床标志物研究进展[J]. 中华眼底病杂志, 2021, 37(4): 321-327. DOI: 10.3760/cma.j.cn511434-20200703-00318.Chen QY, Zhang XD. Research progress of evaluating the prognosis of anti-vascular endothelial growth factor drug treatment for diabetic macular edema with clinical markers[J]. Chin J Ocul Fundus Dis, 2021, 37(4): 321-327. DOI: 10.3760/cma.j.cn511434-20200703-00318.
|
23. |
马钰, 贺经. 眼前节毒性反应综合征的研究进展[J]. 国际眼科杂志, 2017, 17(4): 669-672. DOI: 10.3980/j.issn.1672-5123.2017.4.20.Ma Y, He J. Research progress of toxic anterior segment syndrome[J]. Int Eye Sci, 2017, 17(4): 669-672. DOI: 10.3980/j.issn.1672-5123.2017.4.20.
|